eGenesis Promotes Michael Curtis, Ph.D., to Chief Executive Officer
April 19, 2022 08:30 ET
|
eGenesis
Dr. Curtis succeeds Paul Sekhri, who remains on Board of Directors Reflects company’s focus on advancement of portfolio toward clinical development CAMBRIDGE, Mass., April 19, 2022 (GLOBE...
eGenesis Appoints Eliezer Katz, M.D., FACS, as Chief Medical Officer
April 04, 2022 08:30 ET
|
eGenesis
CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- eGenesis, a gene-editing and genome-engineering company developing human-compatible organs and cells, today announced the appointment of Eliezer...
eGenesis Announces Research Collaboration with the University of Miami to Evaluate Human Compatible Islet Cells in Diabetes Model
March 09, 2022 08:30 ET
|
eGenesis
CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- eGenesis, a gene-editing company developing human-compatible (HuCo™) organs and cells, today announced the initiation of a research collaboration...
eGenesis Appoints Bradford Smith as an Independent Member of Its Board of Directors
June 09, 2021 08:00 ET
|
eGenesis
CAMBRIDGE, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- eGenesis, a gene-editing and genome-engineering company developing human-compatible organs and cells, today announced the appointment of...
eGenesis Expands Research Collaboration with Leading Academic Medical Center
April 01, 2021 08:00 ET
|
eGenesis
Collaboration will now include in vivo testing of lead kidney xenotransplant program in addition to pancreatic islet xenotransplant program CAMBRIDGE, Mass., April 01, 2021 (GLOBE NEWSWIRE) --...
eGenesis Appoints Veteran Financial Executive, Sapna Srivastava, Ph.D., as Chief Financial Officer
March 04, 2021 08:00 ET
|
eGenesis
CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- eGenesis, a gene-editing and genome-engineering company developing human-compatible organs, tissues, and cells, today announced the appointment...
eGenesis Announces $125 Million Series C Financing
March 02, 2021 08:00 ET
|
eGenesis
CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- eGenesis, a gene-editing and genome-engineering company developing human-compatible organs, tissues, and cells, today announced the successful...
eGenesis Announces Research Collaboration with Leading Academic Medical Center
November 05, 2020 08:30 ET
|
eGenesis
CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company using breakthrough gene editing technologies for the development of safe and effective human-compatible organs,...
eGenesis Appoints Veteran Biotechnology Development Executive, Michael Curtis, Ph.D., as President of Research & Development
September 01, 2020 08:00 ET
|
eGenesis
CAMBRIDGE, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company using breakthrough gene editing technologies for the development of safe and effective human-compatible organs,...
eGenesis Appoints Accomplished Biopharmaceutical Executive, Peter Hanson, DVM, Ph.D., as Chief Operating Officer
July 01, 2020 08:00 ET
|
eGenesis
CAMBRIDGE, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company using breakthrough gene editing technologies for the development of safe and effective human-compatible organs,...